肺癌患者末梢血リンパ球のＩＬ‐２によるキラー（ＬＡＫ）活性発現能と単球によるその調節

DOI Web Site

書誌事項

タイトル別名
  • Lymphokine (IL-2)-activated killer (LAK) activity and its regulation by blood monocytes in patients with lung cancer.

この論文をさがす

抄録

The effect of lung cancer on the ability of blood lymphocytes to generate lymphokine (IL-2)-activated killer (LAK) activity and of monocytes to regulate the LAK induction were examined. Highly purified lymphocytes (> 99%) and monocytes (> 90%) were separated by counter-flow centrifugal elutriation. LAK activity against Daudi cells was measured by 4-hr 51Cr release assay. Results showed that the abilities of blood lymphocytes of healthy donors and lung cancer patients to generate LAK activity were similar. Blood monocytes of lung cancer patients significantly augmented the LAK induction at similar levels as did monocytes of healthy donors. When monocytes were stimulated with endotoxin, the monocytes of all healthy donors markedly suppressed LAK induction, whereas the LAK induction was suppressed by monocytes obtained from 7 out of 12 cancer patients, but augmented by monocytes from the remaining 5 patients. Thus, lymphocytes of patients with lung cancer can respond to IL-2 by generating LAK activity, which can be up-regulated by fresh monocytes. These findings indicate that the adoptive immunotherapy with LAK cells and IL-2 could be useful in the treatment of lung cancer.

収録刊行物

  • 肺癌

    肺癌 30 (2), 223-229, 1990

    特定非営利活動法人 日本肺癌学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ